.4

NR

(A) DM 19.6%, CAD 26.8%
(B) DM 20.2%, CAD 26.3%

Antiplatelet therapy,
antihypertensive treatment,
and lipid-lowering therapy

Kolos et al,4 2015
(AMTEC trial)
Russia

(A) 24
(B) 31

(A) 66.1
(B) 6